TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07665892: Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma

Sponsor: Aspeya, Inc. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$656,880

Rescue Site Savings

+$422,280

Unlock Full NCT07665892 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07665892 Rescue Dossier →